NEWS

News Articles

Charles River pens Takeda early-stage drugs deal

January 13, 2020

At the annual J.P. Morgan Healthcare Conference, major CRO Charles River Laboratories and Japanese Big Pharma Takeda announced a new preclinical tie-up. The pair will “launch multiple integrated programs across Takeda’s four core therapeutic areas,” they said in a statement, namely: oncology, gastroenterology, neuroscience and rare disease, with Charles River being tasked with moving its preclinical…

Read More

Augusta University Health announces first-ever chief innovation officer

January 6, 2020

Mallary Myers, a national leader in clinical innovation, has been named vice president/chief innovation officer for Augusta University Health, effective Jan. 3. In this role, Myers will be responsible for promoting a culture of innovation across the health system, including working closely with hospital leadership and AU Health Information Technology to nurture concepts to streamline overall health…

Read More

Boehringer Ingelheim launches VAXXITEK® HVT+IBD+ND, a vaccine that protects poultry from three diseases

January 6, 2020

DULUTH, Ga. January 6, 2020 – Boehringer Ingelheim’s U.S. Animal Health Business launched a vaccine Monday to protect poultry from three diseases. VAXXITEK® HVT+IBD+ND provides a strong immune foundation and optimized protection against Marek’s Disease, Infectious Bursal Disease (classic and variant types) and Newcastle Disease. Until now, Boehringer Ingelheim has offered two vaccines that guard against the…

Read More

Avanos Medical appoints new chief financial officer

December 30, 2019

Avanos Medical (NYSE:AVNS) today said it appointed Michael Greiner as senior VP and chief financial officer, effective Jan. 1. Greiner will be responsible for the Alpharetta, Ga.-based company’s global finance and information technology organizations. He will report to CEO Joe Woody. Prior to joining Avanos Medical, Greiner served as executive VP and CFO of AngioDynamics. He…

Read More

CryoLife Receives FDA Authorization to Commence PROACT Xa Clinical Trial

December 23, 2019

CryoLife, Inc. (NYSE: CRY), a leading cardiac and vascular surgery company focused on aortic disease, announced today that it has received authorization from the U.S. Food and Drug Administration (FDA) pursuant to an Investigational New Drug (IND) application to begin the PROACT Xa clinical trial, a prospective, randomized, trial to determine if patients with an On-X mechanical aortic…

Read More

Biotech company Dendreon extends metro Atlanta lease

December 18, 2019

Dendreon Pharmaceuticals has signed a 10-year lease agreement to maintain its 155,000-square-foot immunotherapy manufacturing facility in Union City, Ga. Dendreon is the maker of Provenge, an immunotherapy treatment for prostate cancer.  “Dendreon has been a proud member of the greater Atlanta community since 2009, and we are thrilled to extend our presence here,” said Christina Yi,…

Read More